Septic Shock-Pipeline Review, H2 2015

Septic Shock-Pipeline Review, H2 2015

  • Products Id :- GMDHC7234IDB
  • |
  • Pages: 83
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Septic Shock-Pipeline Review, H2 2015


Global Markets Direct's, 'Septic Shock-Pipeline Review, H2 2015', provides an overview of the Septic Shock's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Septic Shock, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Septic Shock and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Septic Shock

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Septic Shock and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Septic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Septic Shock pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Septic Shock

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Septic Shock Overview 9

Therapeutics Development 10

Pipeline Products for Septic Shock-Overview 10

Pipeline Products for Septic Shock-Comparative Analysis 11

Septic Shock-Therapeutics under Development by Companies 12

Septic Shock-Therapeutics under Investigation by Universities/Institutes 14

Septic Shock-Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Septic Shock-Products under Development by Companies 18

Septic Shock-Products under Investigation by Universities/Institutes 20

Septic Shock-Companies Involved in Therapeutics Development 21

Adrenomed AG 21

Ferring International Center S.A. 22

Huons Co., Ltd. 23

InflaRx GmbH 24

Lixte Biotechnology Holdings, Inc. 25

Noxxon Pharma AG 26

Orion Oyj 27

Peptinov SAS 28

Pharmazz, Inc. 29

Spider Biotech 30

Takeda Pharmaceutical Company Limited 31

XImmune AB 32

Septic Shock-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

adrecizumab-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

AM-12-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

BC-1215-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

BTZO-2-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

C-10-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

HBN-1-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

HBN-3-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

HBN-4-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

HU-003-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

IFX-1-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

LB-100-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

LB-102-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

LB-1148-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

levosimendan-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

MFH-147-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

NOXD-20-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

PMZ-2010-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

R-190-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

SB-056-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

selepressin-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Small Molecule to Inhibit TNF for Septic Shock-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

SP-14-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

SP-9-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Synthetic Peptides for Inflammation and Infectious Disorders-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Septic Shock-Recent Pipeline Updates 71

Septic Shock-Dormant Projects 76

Septic Shock-Discontinued Products 77

Septic Shock-Product Development Milestones 78

Featured News & Press Releases 78

Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan 78

Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients 79

Feb 02, 2015: Leading BioSciences Receives FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using LB1148 To Treat Septic Shock 80

Jan 02, 2013: Adrenomed Develops New Drug to Reduce Mortality from Septic Shock 81

Appendix 82

Methodology 82

Coverage 82

Secondary Research 82

Primary Research 82

Expert Panel Validation 82

Contact Us 82

Disclaimer 83

List of Tables

Number of Products under Development for Septic Shock, H2 2015 10

Number of Products under Development for Septic Shock-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Development, H2 2015 16

Comparative Analysis by Unknown Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Development by Companies, H2 2015 (Contd...1) 19

Products under Investigation by Universities/Institutes, H2 2015 20

Septic Shock-Pipeline by Adrenomed AG, H2 2015 21

Septic Shock-Pipeline by Ferring International Center S.A., H2 2015 22

Septic Shock-Pipeline by Huons Co., Ltd., H2 2015 23

Septic Shock-Pipeline by InflaRx GmbH, H2 2015 24

Septic Shock-Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015 25

Septic Shock-Pipeline by Noxxon Pharma AG, H2 2015 26

Septic Shock-Pipeline by Orion Oyj, H2 2015 27

Septic Shock-Pipeline by Peptinov SAS, H2 2015 28

Septic Shock-Pipeline by Pharmazz, Inc., H2 2015 29

Septic Shock-Pipeline by Spider Biotech, H2 2015 30

Septic Shock-Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 31

Septic Shock-Pipeline by XImmune AB, H2 2015 32

Assessment by Monotherapy Products, H2 2015 33

Number of Products by Stage and Target, H2 2015 35

Number of Products by Stage and Mechanism of Action, H2 2015 37

Number of Products by Stage and Route of Administration, H2 2015 39

Number of Products by Stage and Molecule Type, H2 2015 41

Septic Shock Therapeutics-Recent Pipeline Updates, H2 2015 71

Septic Shock-Dormant Projects, H2 2015 76

Septic Shock-Discontinued Products, H2 2015 77

List of Figures

Number of Products under Development for Septic Shock, H2 2015 10

Number of Products under Development for Septic Shock-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Early Stage Products, H2 2015 16

Assessment by Monotherapy Products, H2 2015 33

Number of Products by Top 10 Targets, H2 2015 34

Number of Products by Stage and Top 10 Targets, H2 2015 34

Number of Products by Top 10 Mechanism of Actions, H2 2015 36

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 36

Number of Products by Routes of Administration, H2 2015 38

Number of Products by Stage and Routes of Administration, H2 2015 38

Number of Products by Molecule Types, H2 2015 40

Number of Products by Stage and Molecule Types, H2 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Adrenomed AG

Ferring International Center S.A.

Huons Co., Ltd.

InflaRx GmbH

Lixte Biotechnology Holdings, Inc.

Noxxon Pharma AG

Orion Oyj

Peptinov SAS

Pharmazz, Inc.

Spider Biotech

Takeda Pharmaceutical Company Limited

XImmune AB

Septic Shock Therapeutic Products under Development, Key Players in Septic Shock Therapeutics, Septic Shock Pipeline Overview, Septic Shock Pipeline, Septic Shock Pipeline Assessment

select a license

Single User License
USD 2000 INR 128780
Site License
USD 4000 INR 257560
Corporate User License
USD 6000 INR 386340



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]